Sanofi (NASDAQ:SNY) Stock

Sanofi

NYSE

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Biotech

Large Cap

News

Health Care

General

Sanofi&#39;s Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

FDA Approves Sanofi&#39;s Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

Contracts

Sanofi and J&amp;J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi&#39;s Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.

Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

stock buyback

Equities

Buybacks

Movers

LRLCF

LRLCY

Sanofi has purchased 2.3% of its shares from L&#39;Oréal SA as part of its share repurchase program. The €3 billion deal involves acquiring 29.6 million shares at €101.50 each, with cancellation expected by April 29, 2025. 

Sanofi Buys Back ~$3 Billion In Shares From L&#39;Oréal: Details

Sanofi SA

Synthetify

SUNNYLIFE GLOBAL INC by Sunnylife Global, Inc.

Sunnylife Global Inc

Synergy CHC Corp

VITAL ENERGY INC (CDA) by Vital Energy, Inc.

Vital Energy Inc

SANY HEAVY EQUIP INTL HLD by Sany Heavy Equipment International Holdings Co.

Sany Heavy Equipment International Holdings Co Ltd

Sanofi And CD&R Finalize Share Purchase Agreement For 50% Stake In Opella

On Friday, the FDA approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Merilog as a biosimilar to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a>
As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes" rel="noreferrer noopener">approval </a>is for a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.
Merilog is the third insulin biosimilar product the FDA has approved, joining the two long-acting insulin biosimilar products the agency approved in 2021.
A biosimilar is a &#8220;biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product).&#8221; The FDA has approved 65 biosimilar products to date.
Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs, or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient&#8217;s needs.
Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions, and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain, and swelling of hands and feet.
In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to&nbsp;lower the price of its best-selling insulin product, Lantus <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">(insulin glargine), by 78%</a>.
Sanofi said it would cap a&nbsp;Lantus patient&#8217;s monthly out-of-pocket cost at $35 for all patients with commercial insurance.&nbsp;
Also, in 2023, Sanofi acquired&nbsp;Provention Bio for $25.00 per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31318877/provention-bios-2-9b-acquisition-a-strategic-fit-for-sanofi" rel="noreferrer noopener">approximately $2.9 billion</a>.
The transaction adds a type 1 diabetes therapy to Sanofi&#8217;s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.&nbsp;
In November, Doctors Without Borders/Médecins Sans Frontières highlighted that&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk, and Sanofi, which dominate the global insulin market, have the power to set high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price" rel="noreferrer noopener">prices that restrict access</a>.
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
Price Action: SNY stock is down 0.59% at $54.18 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Image by HJBC via Shutterstock

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

<ul>
<li>If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025</li>
<li>Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo</li>
<li>BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions</li>
</ul>

REGN

Regeneron And Sanofi Announce FDA Priority Review For Dupixent In Bullous Pemphigoid, With Approval Decision Expected By June 2025

Soros Fund Management Cuts Share Stake In Sanofi By 50% To 200,000 Sponsored ADRs

U.S. FDA Approves Sanofi-Aventis U.S' Merilog & Merilog Solostar, Biosimilars To Novo Nordisk's Novolog

Sanofi's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NYSE">SNY</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 4.88 million shares sold short, which is 0.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sanofi Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739554222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sanofi has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sanofi's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sanofi's peer group average for short interest as a percentage of float is 4.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Sanofi?

<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm" title="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm">https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm</a>

CVAC

MRNA

NVAX

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic&nbsp;E. coli.
The E.mbrace <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-02-13-06-00-00-3025576" rel="noreferrer noopener">study</a> is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine candidate compared to a placebo in the prevention of IED, which includes sepsis and bacteremia (blood infections).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43142442/sanofi-genzyme-facility-fda-quality-lapses" rel="noreferrer noopener">Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses</a>
An independent data monitoring committee (IDMC) conducted a scheduled review of the E.mbrace phase 3 study.
The companies determined that the vaccine candidate was not sufficiently effective at preventing invasive&nbsp;E. coli disease (IED) compared to placebo.
No safety signals related to the vaccine candidate were identified, and throughout the study, investigators ensured that participants who developed IED received prompt treatment and care.
In October 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson &amp; Johnson company, to develop and commercialize the vaccine candidate.
Under the terms of the agreement, both parties agreed to co-fund current and future research and development costs. Sanofi paid $250 million in upfront and development milestones to be followed by commercial milestones.
The study was initiated in June 2021 enrolling adults aged 60 years or older in stable health with a history of urinary tract infection in the past two years.
As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment negatively impacts the full-year IFRS EPS reported in the Q4 2024 results press release on January 30, 2025, by 15 cents, from 4.59 euros previously to 4.44 euros now.
However, there is no impact on the business net income/EPS, which remain unchanged, respectively, at 8.91 billion euros/ 7.12 euros (non-IFRS).
Price Action: As of Thursday, SNY stock was up 0.18% at $54.66 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43676723/third-harmonic-bio-initiates-strategic-review-lays-off-50-staff-citing-competitive-landscape" target="_blank" rel="noreferrer noopener">Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape</a></li>
</ul>
Image by HJBC via Shutterstock

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
<ul>
<li>Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E. coli disease</li>
<li>No safety signals related to the vaccine candidate were identified</li>
</ul>
Financial considerations As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment impacts negatively the full-year IFRS EPS reported in the Q4 2024 results press release on January 30, 2025, by €0.15 from €4.59 previously to €4.44 now. This adjustment&nbsp;will be included&nbsp;in Sanofi's Form 20-F for 2024 to be filed with the US Securities and Exchange Commission. However, there is no impact to the business net income / business EPS remaining unchanged respectively at €8,912 million / €7.12 (non-IFRS). There is no change to the financial guidance for 2025

Sanofi And Janssen Halt Phase 3 E. coli Vaccine Trial Following Interim Analysis Showing Insufficient Efficacy; Sanofi Records €250M Impairment Charge

On February 6, 2025, Sanofi has entered into a mandate with an investment service provider for the second tranche of this program. Under the terms of this mandate, Sanofi will repurchase its own shares for a total consideration of up to €2 billion, between February 7, 2025 and December 31, 2025 at the latest.

Sanofi Secures €2B Share Buyback Mandate As Part Of €5B 2025 Repurchase Plan

Pharmaceutical and healthcare company Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) has announced the purchase of 2.3% of its shares from its long-standing investor, L&#8217;Oréal SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LRLCF#OTC">LRLCF</a>), as part of its <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-02-03-06-30-00-3019186" rel="noreferrer noopener">ongoing share repurchase initiative</a>.
Sanofi&#8217;s Board of Directors has authorized the purchase of 29.6 million shares from L&#8217;Oréal, reflecting a discount of 2.8% to the closing price on January 31, 2025.
The total transaction amounts to 3 billion euros ($3.07 billion) and after the deal is finalized, the acquired shares will be canceled by Sanofi no later than April 29, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43395171/walmart-canada-to-invest-about-3-8-billion-over-five-years" rel="noreferrer noopener">Walmart Canada To Invest About $3.8 Billion Over Five Years</a>
&#8220;We are pleased to retain L&#8217;Oréal as one of our largest shareholders. This transaction highlights Sanofi&#8217;s dedication to sustainable value creation while upholding our strategic priorities and preserving the strength of our key partnerships,&#8221; said CFO François Roger.
The acquisition will take place through an off-market block transaction, with no additional conditions, and is anticipated to be finalized in the coming days.
After the shares are canceled, L&#8217;Oréal will retain 7.2% of Sanofi&#8217;s total share capital and 13.1% of its voting rights.
The action is anticipated to boost Sanofi&#8217;s earnings per share, strengthening the company&#8217;s financial standing and providing additional value to its shareholders.
For L&#8217;Oréal, the <a target="_blank" href="https://www.loreal.com/en/press-release/group/agreement-between-loreal-and-sanofi/" rel="noreferrer noopener">transaction </a>is aimed at improving its financial structure, especially considering its recent acquisitions, while also broadening its financing sources.
Price Action: SNY shares are trading lower by 1.79% at $53.37 in premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43399775/colgate-palmolive-beats-q4-eps-estimates-but-faces-sales-struggles-says-analyst" target="_blank" rel="noreferrer noopener">Colgate-Palmolive Remains One Of The Highest-Quality Names Despite Tough End-Market Backdrop: Goldman Sachs</a></li>
</ul>
Image: Shutterstock/ bangoland.

Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details

The acquisition is structured as an off-market block trade and is not subject to any specific conditions. The acquisition is pursuant to an agreement approved by Sanofi's Board of Directors as a related-party agreement, in compliance with article L.225-38 of the French Commercial Code, entered into on February 2, 2025. It is expected to be completed in the coming days. The transaction will involve the acquisition of 29,556,650 shares at a price of €101.50 per share, reflecting a discount of 2.8% to the closing price on January 31, 2025. The total consideration of the transaction amounts to €3 billion. Shares acquired from L'Oréal will be cancelled at the latest on April 29, 2025. The acquisition of these shares is expected to be accretive to Sanofi's earnings per share, further enhancing shareholder value.
After cancellation of the shares and excluding treasury shares, L'Oréal will own 7.2% of Sanofi, with 13.1% of voting rights1.

Sanofi Acquires 2.3% Of Its Shares From L'Oréal In €3B Buyback To Enhance Shareholder Value

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant&nbsp;
<ul>
<li>Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma&nbsp;</li>
<li>Second approval in China in three weeks following the R/R MM indication announced on January 13, 2025</li>
</ul>

Sanofi's Sarclisa Becomes First Anti-CD38 Therapy Approved In China For Newly Diagnosed Multiple Myeloma Patients Ineligible For Transplant

Trump Health Sec Nominee Kennedy Says He Will Support Development Of Vaccines For Bird Flu

WIIM

Sanofi shares are trading higher after the company reported better-than-expected Q4 revenue results.

Earnings

AAPL

ABCB

ALGM

APPF

Adtalem Global Education Inc. Common Stock

ATGE

BAFN

BBVA

BHLB

BOOT

CACC

CHKP

CIVB

CMCSA

CNOB

COUR

CSWI

CVCO

DECK

FBIZ

FCFS

FFWM

FINW

FISI

FLWS

FRME

GSIT

INTC

KLAC

KRNY

LPLA

MBLY

MBUU

NTCT

ONEW

PFSI

REAL

SCSC

SHEL

SILC

SIRI

SKYW

STBA

STEL

Earnings Scheduled For January 30, 2025

Guidance&nbsp;
&nbsp;In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5 . Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback).6 • Sanofi intends to execute a share buyback program in 2025 of €5 billion. Shares will be purchased preferably through block trades and in the open market with the purpose of cancellation

Guidance

Sanofi 2025 Guidance: Sales To Grow Mid-To-High Single Digits (CER), Business EPS To Rise Low Double Digits (CER); Plans A €5B Share Buyback

Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported quarterly earnings of $0.70 per share which missed the analyst consensus estimate of $0.74 by 5.54 percent. This is a 21.46 percent decrease over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $11.275 billion which beat the analyst consensus estimate of $11.162 billion by 1.01 percent. This is a 4.07 percent decrease over sales of $11.753 billion the same period last year.

Earnings Beats

Earnings Misses

Sanofi Q4 2024 Adj. EPS $0.70 Misses $0.74 Estimate, Sales $11.275B Beat $11.162B Estimate

Piper Sandler analyst David Amsellem reiterated the Overweight rating on Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">with a price forecast of $30.</a>
Amsellem writes that he hosted a call with a top gastroenterologist who treats many ulcerative colitis and Crohn&#8217;s disease patients. The doctor specializes in managing treatment-experienced and refractory cases at a major referral center.
From the call, the analyst notes that feedback on Teva's/Sanofi's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) anti-TL1A antagonist duvakitug, along with the broader anti-TL1A class, suggests these agents could play a significant role in treating both ulcerative colitis and Crohn&#8217;s disease, which is supported by competitive data.
Amsellem highlights that according to the featured expert, biomarkers are crucial, and they are particularly interested in studies/data stratified by biomarkers.
The analyst will closely follow what Teva shares on this at the upcoming ECCO meeting.
Both Merck &amp; Company, Inc. and Roche Holding Ltd are also stratifying their anti-TL1A studies by biomarkers.
The expert considers that biomarkers could greatly benefit the broader inflammatory bowel disease (IBD) field if they are easy to assess and help predict clinical response.
While Teva/Sanofi&#8217;s all-comers Phase III program for duvakitug is commercially reasonable, the goal is to address a wide ulcerative colitis and Crohn&#8217;s disease patient audience.
Price Action: TEVA shares are trading lower by 1.47% to $21.46 at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43254923/7-ai-infrastructure-stocks-plunge-over-20-outpace-semiconductor-rout-as-deepseek-upends-investment-landscape" target="_blank" rel="noreferrer noopener">7 AI Infrastructure Stocks Plunge Over 20%, Outpace Semiconductor Rout As DeepSeek Upends Investment Landscape</a></li>
</ul>
Photo by Ralf Liebhold via Shutterstock.

Analyst Color

Price Target

Reiteration

Markets

Analyst Ratings

RHHBY

TEVA

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data

Global health concerns escalated Monday as the U.S. Centers for Disease Control and Prevention reportedly halted collaboration with the World Health Organization, coinciding with the discovery of a rare H5N9 bird flu strain in California and upcoming Senate confirmation hearings for vaccine skeptic Robert F. Kennedy Jr.
What Happened: The developments sent ripples through healthcare stocks, with vaccine manufacturers showing mixed reactions. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) edged up 0.58%, while Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) gained 2.95% amid heightened focus on potential bird flu preparedness.
CDC official John Nkengasong&#8216;s Sunday memo, <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">viewed</a> by The Associated Press, ordered an immediate stop to all WHO collaborations, catching health experts off guard as the U.S. faces multiple health challenges, including 13 measles outbreaks this year.
The first U.S. H5N9 outbreak, detected at a Merced County duck farm alongside the more common H5N1 strain, led to the culling of 119,000 birds, Reuters reported.
The discovery comes as egg prices nationwide hit $4.15 per dozen in December. The United States Department of Agriculture is projecting a further 20% increase this year due to ongoing bird flu impacts, according to a separate Associated Press <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">report</a>.
The timing is particularly significant as Kennedy, known for his vaccine skepticism, faces Senate confirmation hearings this week for Health and Human Services Secretary. His potential appointment has already influenced market sentiment, with some vaccine stocks experiencing volatility.
&#8220;The concurrent WHO separation and emerging health threats create significant uncertainty for healthcare investors,&#8221; said Dr. Jeffrey Klausner, a University of Southern California public health expert.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43256425/nvidia-says-deepseek-an-illustration-of-how-new-ai-models-can-be-created-while-being-export-control-compliant-amid-600-billion-market-value-plunge">Nvidia Says DeepSeek An &#8216;Illustration&#8217; Of How New AI Models Can Be Created While Being Export-Control Compliant Amid $600 Billion Market Value Plunge</a>
Why It Matters: The healthcare sector&#8217;s response reflects broader market concerns. The iShares Genomics Immunology and Healthcare ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>) has gained 1.2% year-to-date, while <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">major vaccine producers</a> maintain substantial government contracts for flu preparedness.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), GlaxoSmithKline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), and other manufacturers secured $72 million in federal funding last October for bird flu vaccine production. Moderna separately received $176 million from BARDA for mRNA-based H5N1 vaccine development.
The CDC decision follows President Donald Trump&#8216;s executive order to withdraw from WHO, though the complete withdrawal requires congressional <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">approval and a one-year notice period</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43256454/bitcoin-ethereum-dogecoin-recover-as-deepseek-troubles-mount-for-us-tech-stocks-analyst-suggests-btc-could-hit-fresh-highs-over-upcoming-two-weeks">Bitcoin, Ethereum, Dogecoin Recover As DeepSeek Troubles Mount For US Tech Stocks: Analyst Suggests BTC Could Hit Fresh Highs Over Upcoming Two Weeks</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

IDNA

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?

Press Releases

Sanofi ships U.S. influenza vaccines for the 2024/25 season

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza

Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA

Opinion

Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

Beyfortus® immunization to protect infants from RSV has begun

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

ANVS

AVTE

CTRX

DVAX

GTHX

HALO

HPTX

HZNP

ONCY

TARS

TSX:ONC

ZNTL

ZSPH

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Sanofi

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga